Table A7.

Disaggregated cost and outcomes of brexucabtagene autoleucel vs. BSC based on 1000 iterations.

	Brexucabtagene Autoleucel	BSC	Incremental
Total discounted years	11.21	1.72	9.49
Pre-progression	8.01	1.50	6.51
Post-progression	3.20	0.22	2.98
Total discounted QALYs	8.31	1.31	7.00
Pre-progression	6.28	1.17	5.11
Pre-progression, pre-cure point	1.99	1.03	0.95
Pre-progression, post-cure point	4.29	0.14	4.15
Post-progression	2.07	0.14	1.92
Adverse events	−0.04	−0.01	−0.03
Total discounted costs	CAD 689,636	CAD 68,066	CAD 621,571
Total treatment-related costs	CAD 592,182	CAD 27,701	CAD 564,480
Total drug acquisition	CAD 533,523	CAD 26,989	CAD 506,534
Total apheresis	CAD 1374	CAD 0	CAD 1374
Total drug administration	CAD 211	CAD 713	CAD −502
Total lymphodepletion chemotherapy	CAD 646	CAD 0	CAD 646
Total bridging therapy	CAD 222	CAD 0	CAD 222
Total hospitalization	CAD 56,206	CAD 0	CAD 56,206
Total disease management	CAD 56,500	CAD 4692	CAD 51,808
Pre-progression	CAD 3996	CAD 1145	CAD 2851
Post-progression	CAD 52,504	CAD 3547	CAD 48,957
Other costs	CAD 40,954	CAD 35,672	CAD 5282
End-of-life care	CAD 29,603	CAD 34,591	CAD −4988
Adverse events	CAD 11,351	CAD 1081	CAD 10,270
		Cost/QALY	CAD 88,814

Abbreviations: BSC, best supportive care; LYs, life-years; QALYs, quality-adjusted life-years.